Winslow Evans & Crocker’s Puma Biotechnology PBYI Stock Holding History

Winslow Evans & Crocker’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-14	Closed	-$886	–	1155
2018 Q1	$886	Buy	+14	New	+$1.05K	﹤0.01%	1074

Other funds holding PBYI

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Winslow Evans & Crocker's PBYI Position: Q2 2018 in Review

Winslow Evans & Crocker sold out of Puma Biotechnology (PBYI) in Q2 2018, closing a stake of 14 shares — an estimated $886 sold.

Winslow Evans & Crocker first reported a position in PBYI in Q1 2018 and held it in 1 quarter. The position peaked at $886 in Q1 2018. 174 funds tracked by Wall St. Rank hold PBYI as of Q2 2018.

Winslow Evans & Crocker reported no remaining Puma Biotechnology position as of Q2 2018 after selling out during the quarter.
Winslow Evans & Crocker sold 14 Puma Biotechnology shares in Q2 2018, an estimated $886.
Winslow Evans & Crocker first reported a position in Puma Biotechnology in Q1 2018 and held it in 1 quarter.
Winslow Evans & Crocker's Puma Biotechnology position peaked at $886 in Q1 2018.
174 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2018.

Based on Winslow Evans & Crocker's 13F filing for Q2 2018, filed 17 Jul 2018.